Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on September 19, 2002; DOI 10.1182/blood-2002-06-1665.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-06-1665v1
101/3/998    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grader-Beck, T.
Right arrow Articles by Boussiotis, V. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grader-Beck, T.
Right arrow Articles by Boussiotis, V. A
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted June 10, 2002
Accepted September 2, 2002

cAMP inhibits both Ras and Rap1 activiation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression

Thomas Grader-Beck, Andre A F L van Puijenbroek, Lee M Nadler, and Vassiliki A Boussiotis*

Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA

* Corresponding author; email: vassiliki_boussiotis{at}dfci.harvard.edu.

Cyclic AMP (cAMP) is a negative regulator of T cell activation. However, the effects of cAMP on signaling pathways that regulate cytokine production and cell cycle progression remain unclear. Here, using primary human T lymphocytes in which endogenous cAMP was increased by the use of Forskolin and IBMX, we show that increase of cAMP resulted in inhibition of TCR/CD3-plus-CD28-mediated T cell activation and cytokine production and blockade of cell cycle progression at the G1 phase. Increase of cAMP inhibited Ras activation and phosphorylation of MEK downstream targets ERK1/2, and phosphatidylinositol-3-kinase (PI3K) downstream target protein kinase B (PKB;c-Akt). These functional and biochemical events were secondary to the impaired activation of ZAP-70 and phosphorylation of LAT and did not occur when cells were stimulated with phorbol ester, which bypasses the TCR proximal signaling events and activates Ras. Increase of cAMP also inhibited activation of Rap1 mediated by TCR/CD3-plus-CD28. Importantly, inhibition of Rap1 activation by cAMP was also observed when cells were stimulated with phorbol ester, although under these conditions Ras was activated and cells progressed into the cell cycle. Thus, TCR-plus-CD28-mediated activation of ERK1/2 and PKB, cytokine production and cell cycle progression, all of which are inhibited by cAMP, require activation of Ras but not Rap1. These results indicate that signals which regulate cAMP levels after encounter of T cells by antigen will likely determine the functional fate towards clonal expansion or repression of primary T cell responses.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
D. Pozo, P. Anderson, and E. Gonzalez-Rey
Induction of Alloantigen-Specific Human T Regulatory Cells by Vasoactive Intestinal Peptide
J. Immunol., October 1, 2009; 183(7): 4346 - 4359.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Mor, J. P. Wynne, I. M. Ahearn, M. L. Dustin, G. Du, and M. R. Philips
Phospholipase D1 Regulates Lymphocyte Adhesion via Upregulation of Rap1 at the Plasma Membrane
Mol. Cell. Biol., June 15, 2009; 29(12): 3297 - 3306.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S.-W. Kim, D. Rai, M. R. McKeller, and R. C. T. Aguiar
Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL
Blood, June 11, 2009; 113(24): 6153 - 6160.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Hong, L. Lou, S. Gupta, F. Ribeiro-Neto, and D. L. Altschuler
A Novel Epac-Rap-PP2A Signaling Module Controls cAMP-dependent Akt Regulation
J. Biol. Chem., August 22, 2008; 283(34): 23129 - 23138.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. G. Smith, F. Wang, K. N. Wilkinson, K. J. Savage, U. Klein, D. S. Neuberg, G. Bollag, M. A. Shipp, and R. C. T. Aguiar
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma
Blood, January 1, 2005; 105(1): 308 - 316.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Wang, R. A. Barke, R. Charboneau, H. H. Loh, and S. Roy
Morphine Negatively Regulates Interferon-{gamma} Promoter Activity in Activated Murine T Cells through Two Distinct Cyclic AMP-dependent Pathways
J. Biol. Chem., September 26, 2003; 278(39): 37622 - 37631.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020